Can We Prevent Fatal Liver Failure under Valproate?

Valproic acid (VPA) has been used as an anticonvulsant for more than 30 years. Meanwhile, VPA has also been approved by the FDA for the treatment of bipolar disorders. We report the case of a 58-year-old female patient, who died from liver failure, probably due to treatment with VPA. The patient was admitted for bipolar affective disorder, currently depressed. Duloxetine was introduced as an antidepressant, VPA as a prophylactic treatment. 18 days after starting VPA treatment, the patient was admitted to a medical emergency unit due to diarrhea, gait ataxia and elevated temperature. Liver enzymes and creatinine were massively elevated. Due to acute hepatic failure, liver transplantation was performed. Histologically, extensive necrosis was demonstrated, with less than 5% of liver tissue preserved. The patient died of sepsis and multi-organ failure after five months. In this patient, liver failure occurred within less than three weeks after introduction of VPA and duloxetine. No other risk factors could be identified. The present case suggests that careful attention to clinical symptoms related to liver failure is of prime importance in VPA therapy to avoid a fatal outcome. A more intensive monitoring of liver enzymes as currently recommended after initiating VPA therapy might be considered.

References

• 1 Basile G, Villari D, Gangemi S. et al . Candesartan cilexetil-induced severe hepatotoxicity.  J Clin Gastroenterol. 2003;  36 273-275
• 2 Bauer M. Fatal hepatic failure and valproate.  Am J Psychiatry. 2005;  162 192
• 3 Bryant AE, Dreifuss FE. Valproic acid hepatic fatalities. III: US experience since 1986.  Neurology. 1996;  46 465-469
• 4 Goodwin GM. Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition-recommendations from the British Association for Psychopharmacology.  J Psychopharmacol. 2009;  23 346-388
• 5 Hanje AJ, Pell LJ, Votolato NA. et al . Case report: fulminant hepatic failure involving duloxetine hydrochloride.  Clin Gastoenterol Hepatol. 2006;  4 912-917
• 6 Harden CL. Therapeutic safety monitoring: what to look for and when to look for it.  Epilepsia. 2000;  41 (Suppl. 8) S37-S44
• 7 Hirschfeld RMA, Bowden CL, Gitlin MJ. et al . American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder.  Am J Psych. 2002;  159 (Suppl.) 4
• 8 König S, Buesing D, Longin E. et al . Valproic acid-induced hepatopathy: nine new fatalities in Germany from 1994 to 2003.  Epilepsia. 2006;  47 2007-2031
• 9 König S, Elger CE, Vassella F. et al . Recommendations for blood studies and clinical monitoring in early detection of valproate associated liver failure. Results of a consensus conference 9 May – 11 May 1997 in Berlin.  Nervenarzt. 1998;  69 835-840
• 10 Naranjo CA, Busto U, Sellers EM. et al . A method for estimating the probability of adverse drug reactions.  Clin Pharmacol Ther. 1981;  30 239-245
• 11 Neuman M, Shear N, Jacobsen-Brown P. et al . CYP2E1-mediated modulation of valproic acid-induced hepatotoxicity.  Clin Biochem. 2001;  34 211-218
• 12 Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs.  Epilepsia. 2007;  48 1223-1244

Correspondence